Hyperlipidemia - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 209
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HF63904127CEN
Leaflet:

Download PDF Leaflet

Hyperlipidemia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Hyperlipidemia - Pipeline Review, H2 2016’, provides an overview of the Hyperlipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
  • The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperlipidemia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hyperlipidemia Overview
Therapeutics Development
Pipeline Products for Hyperlipidemia - Overview
Pipeline Products for Hyperlipidemia - Comparative Analysis
Hyperlipidemia - Therapeutics under Development by Companies
Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes
Hyperlipidemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hyperlipidemia - Products under Development by Companies
Hyperlipidemia - Products under Investigation by Universities/Institutes
Hyperlipidemia - Companies Involved in Therapeutics Development
Acasti Pharma Inc.
Akcea Therapeutics Inc
Allergan Plc
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BASF SE
BCWorld Pharm Co. Ltd.
BioRestorative Therapies, Inc.
Cadila Pharmaceuticals Limited
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
CJ HealthCare Corp.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Esperion Therapeutics, Inc.
Golden Biotechnology Corp.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Hyundai Pharmaceutical Co., Ltd.
Innovent Biologics, Inc.
Jeil Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
Kyorin Pharmaceutical Co., Ltd.
LG Life Science LTD.
LipimetiX Development Inc
Matinas BioPharma Holdings, Inc.
Pfizer Inc.
Pharmena SA
Protalix BioTherapeutics, Inc.
Regeneron Pharmaceuticals Inc
Sancilio & Company, Inc.
Yuhan Corporation
Zydus Cadila Healthcare Limited
Hyperlipidemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile
(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile
(atorvastatin calcium + losartan potassium) - Drug Profile
(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile
(ezetimibe + rosuvastatin calcium) - Drug Profile
(gemigliptin + rosuvastatin calcium) - Drug Profile
(metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile
AC-261066 - Drug Profile
AEM-28 - Drug Profile
AEM-2802 - Drug Profile
AEM-2814 - Drug Profile
ALN-AC3 - Drug Profile
ALN-ANG - Drug Profile
antroquinonol - Drug Profile
ARI-3037MO - Drug Profile
BCWPC-001 - Drug Profile
bempedoic acid - Drug Profile
bezafibrate ER - Drug Profile
BH-03004 - Drug Profile
BioE-1115 - Drug Profile
bococizumab - Drug Profile
BSN-272 - Drug Profile
CAT-2000 Series - Drug Profile
CAT-2003 - Drug Profile
CDX-085 - Drug Profile
centatin - Drug Profile
DWJ-1351 - Drug Profile
etanercept biosimilar - Drug Profile
evolocumab - Drug Profile
gemcabene calcium - Drug Profile
HOB-071 - Drug Profile
HU-012 - Drug Profile
IBI-306 - Drug Profile
icosabutate - Drug Profile
IMMH-007 - Drug Profile
ISIS-APOCIIILRx - Drug Profile
JS-002 - Drug Profile
K-312 - Drug Profile
leucine + niacin - Drug Profile
LTPO-3FA - Drug Profile
MAT-9001 - Drug Profile
MBX-8025 - Drug Profile
MN-002 - Drug Profile
NKPL-66 - Drug Profile
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile
omega-3-carboxylic acids - Drug Profile
PF-06427878 - Drug Profile
PF-06815345 - Drug Profile
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile
REGN-1001 - Drug Profile
saroglitazar - Drug Profile
SC-401 - Drug Profile
Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile
Small Molecule for Hyperlipidemia - Drug Profile
Small Molecule for Hypertriglyceridaemia - Drug Profile
Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile
Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile
TRIA-662 - Drug Profile
volanesorsen sodium - Drug Profile
YH-22189 - Drug Profile
Hyperlipidemia - Dormant Projects
Hyperlipidemia - Discontinued Products
Hyperlipidemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hyperlipidemia, H2 2016
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Investigation by Universities/Institutes, H2 2016
Hyperlipidemia - Pipeline by Acasti Pharma Inc., H2 2016
Hyperlipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016
Hyperlipidemia - Pipeline by Allergan Plc, H2 2016
Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
Hyperlipidemia - Pipeline by Amgen Inc., H2 2016
Hyperlipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
Hyperlipidemia - Pipeline by AstraZeneca Plc, H2 2016
Hyperlipidemia - Pipeline by BASF SE, H2 2016
Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
Hyperlipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016
Hyperlipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016
Hyperlipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
Hyperlipidemia - Pipeline by CJ HealthCare Corp., H2 2016
Hyperlipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016
Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016
Hyperlipidemia - Pipeline by Golden Biotechnology Corp., H2 2016
Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Hyperlipidemia - Pipeline by Huons Co., Ltd., H2 2016
Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H2 2016
Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
Hyperlipidemia - Pipeline by Kowa Company, Ltd., H2 2016
Hyperlipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Hyperlipidemia - Pipeline by LG Life Science LTD., H2 2016
Hyperlipidemia - Pipeline by LipimetiX Development Inc, H2 2016
Hyperlipidemia - Pipeline by Matinas BioPharma Holdings, Inc., H2 2016
Hyperlipidemia - Pipeline by Pfizer Inc., H2 2016
Hyperlipidemia - Pipeline by Pharmena SA, H2 2016
Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Hyperlipidemia - Pipeline by Sancilio & Company, Inc., H2 2016
Hyperlipidemia - Pipeline by Yuhan Corporation, H2 2016
Hyperlipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hyperlipidemia - Dormant Projects, H2 2016
Hyperlipidemia - Dormant Projects (Contd.1), H2 2016
Hyperlipidemia - Dormant Projects (Contd.2), H2 2016
Hyperlipidemia - Dormant Projects (Contd.3), H2 2016
Hyperlipidemia - Dormant Projects (Contd.4), H2 2016
Hyperlipidemia - Dormant Projects (Contd.5), H2 2016
Hyperlipidemia - Dormant Projects (Contd.6), H2 2016
Hyperlipidemia - Dormant Projects (Contd.7), H2 2016
Hyperlipidemia - Dormant Projects (Contd.8), H2 2016
Hyperlipidemia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Hyperlipidemia, H2 2016
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Acasti Pharma Inc.
Akcea Therapeutics Inc
Allergan Plc
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BASF SE
BCWorld Pharm Co. Ltd.
BioRestorative Therapies, Inc.
Cadila Pharmaceuticals Limited
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
CJ HealthCare Corp.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Esperion Therapeutics, Inc.
Golden Biotechnology Corp.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Hyundai Pharmaceutical Co., Ltd.
Innovent Biologics, Inc.
Jeil Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
Kyorin Pharmaceutical Co., Ltd.
LG Life Science LTD.
LipimetiX Development Inc
Matinas BioPharma Holdings, Inc.
Pfizer Inc.
Pharmena SA
Protalix BioTherapeutics, Inc.
Regeneron Pharmaceuticals Inc
Sancilio & Company, Inc.
Yuhan Corporation
Zydus Cadila Healthcare Limited
Skip to top


Hyperlipidemia - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 212 pages
Sotio a.s. - Product Pipeline Review - 2015 US$ 1,200.00 Mar, 2015 · 23 pages
AudioCure Pharma GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 23 pages
CLL Pharma - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 21 pages

Ask Your Question

Hyperlipidemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: